financetom
Business
financetom
/
Business
/
National Bank on CN Rail, CPKC Q4 Update
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
National Bank on CN Rail, CPKC Q4 Update
Dec 4, 2024 11:36 AM

02:14 PM EST, 12/04/2024 (MT Newswires) -- National Bank writes that so far in the fourth quarter, CN's volumes as measured by RTMs are down 3.2% while CPKC's are up 1.4%. Analyst Cameron Doerksen notes that rail volumes have been impacted by port shutdowns on Canada's West Coast and Montreal, but with the ports now back to more normal operations and with tailwinds from a solid Canadian grain crop, Doerksen is optimistic that volumes in the final weeks of the quarter will be positive for both railroads. However, uncertainty around trade stemming from tariff threats from the incoming U.S. Administration may weigh on the shares of both companies into 2025.

National is keeping its Outperform rating on CN Rail as its relative valuation remains attractive.

While National remains positive on CPKC's long-term volume growth outlook, its relative valuation is less compelling. Doerksen is keeping his Sector Perform rating, as the uncertainty around tariffs and trade will have more of an impact on investor sentiment for CPKC shares than CN, at least in the short-term.

Price: 154.05, Change: +0.40, Percent Change: +0.26

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hindenburg Research reveals short position in data center operator Equinix
Hindenburg Research reveals short position in data center operator Equinix
Mar 20, 2024
(Reuters) -Hindenburg Research disclosed a short position in Equinix ( EQIX ) on Wednesday, saying the data center operator trades at elevated levels, has overstated a key profitability metric and faces strong competition from large cloud firms, including Amazon.com. Equinix's ( EQIX ) shares fell 6% in premarket trading, while shares of its rival Digital Realty dropped 4%. The short...
Sector Update: Consumer
Sector Update: Consumer
Mar 20, 2024
08:48 AM EDT, 03/20/2024 (MT Newswires) -- Consumer stocks were steady pre-bell Wednesday as the Consumer Staples Select Sector SPDR Fund (XLP) and Consumer Discretionary Select Sector SPDR Fund (XLY) were recently inactive. Signet Jewelers' ( SIG ) shares were over 9% lower after the company reported fiscal Q4 sales of $2.5 billion, down from $2.67 billion a year earlier....
Exxon Mobil Insider Sold Shares Worth $271,980, According to a Recent SEC Filing
Exxon Mobil Insider Sold Shares Worth $271,980, According to a Recent SEC Filing
Mar 20, 2024
08:49 AM EDT, 03/20/2024 (MT Newswires) -- Darrin L Talley, Vice President, on March 19, 2024, sold 2,400 shares in Exxon Mobil ( XOM ) for $271,980. Following the Form 4 filing with the SEC, Talley has control over a total of 220,621 shares of the company, with 186,500 shares held directly and 34,121 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/34088/000112760224010621/xslF345X03/form4.xml...
Kyowa Kirin's gene therapy most expensive US drug with $4.3 mln price tag
Kyowa Kirin's gene therapy most expensive US drug with $4.3 mln price tag
Mar 20, 2024
March 20 (Reuters) - Orchard Therapeutics, a unit of Japan's Kyowa Kirin ( KYKOF ), priced its newly approved gene therapy for a rare, life-threatening genetic disease on Wednesday at $4.25 million, making it the most expensive drug in the United States. The therapy was approved on Monday, in a first for children with a rare disorder called metachromatic leukodystrophy...
Copyright 2023-2026 - www.financetom.com All Rights Reserved